Key result
Heterotopic heart valve implantation offers a promising transcatheter strategy for severe TR and RHF in high-risk patients.
Why the study?
Severe tricuspid regurgitation is prevalent and undertreated, with optimal medical therapy offering limited impact on systemic venous congestion and surgical correction carrying high operative risk.
Novel strategy demonstrates improved outcomes in severe tricuspid regurgitation, suggesting a new option for high-risk patients.
Tricuspid regurgitation (TR) is a prevalent, undertreated condition associated with debilitating symptoms and poor outcomes. While optimal medical therapy (OMT) remains foundational in heart failure (HF) management, it has limited impact on the pathophysiologic consequences of severe TR; particularly systemic venous congestion, right heart failure, and end-organ dysfunction. Surgical correction carries considerable operative risk, prompting the development of transcatheter strategies for these high-risk patients.
No takes yet. Share an insight, caveat, or question.
Labin et al. (2026) studied this question. Heterotopic heart valve implantation offers a promising transcatheter strategy to address severe tricuspid regurgitation and right heart failure in high-risk patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: